Viral Vector and Plasmid DNA Manufacturing Market Growth, Industry Outlook and Opportunities 2022 – 2029 | DataM Intelligence

DataM Intelligence
The Global Viral Vector and Plasmid DNA Manufacturing Market are expected to grow at a high CAGR of 18.8% during the forecasting period (2022-2029).

Market Overview

The viral vector is called the tool for turning in genetic cloth into cells. The modified viral vector is used as viral vectors in gene remedy. Plasmid DNA is a bacterial smaller, circular, and extrachromosomal DNA used in distinctive molecular genetic studies such as gene therapy, gene transfer, and recombinant DNA generation because of its self-replication property. A gene of interest is transferred into the goal cell for studying the characteristic or expression of a gene.


Download free sample @


Market Dynamics

The marketplace is driven through the growing call for for viral vectors and plasmid DNA manufacturing for growing DNA vaccines, gene therapy, immunotherapy, and others. There are growing viral vectors & plasmid DNA due to their advantages which includes excessive transfection efficiency, effective gene shipping, and solid gene expression. There is an growth within the quantity of clinical research inspecting the viral vectors’ efficacy and protection and plasmid DNA.

There is an increase within the settlement production business release for viral vectors and plasmid DNA production. For instance, in December 2019, Helixmith Co., Ltd. And Genopis had launched the contract production commercial enterprise for plasmid DNA production. The agency would set up additional smaller-scale reactors (60-300 L, 6-30 L) with feasibility runs and start a small-quantity production provider. Genopis is equipped with the right technologies and high-quality systems.

Several agencies are getting into a collaboration with several agencies to manufacture viral vectors and plasmid DNA. For instance, in June 2020, Oxford Biomedica % had entered into a collaboration agreement with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-earnings organisation hooked up to provide the United Kingdom’s first strategic vaccine improvement and superior production functionality. This 5-12 months settlement might involve the companies operating collaboratively to permit the manufacture of viral vector-based vaccines, contributing to a speedy boom within the United Kingdom home capability for this specialized vaccine manufacturing area. Under the phrases of the agreement, VMIC could provide production device for Oxford Biomedica to equip two new GMP production suites inside Oxford Biomedica’s new 7,800 m2 business production center, Oxbox, placed in Oxford, United Kingdom.


Market Segmentation

By Product Type

l Plasmid DNA

l Viral Vector

l Non-Viral Vector


By Application

l Cancer

l Genetic Disorder

l Infectious Disease

l Other Diseases


By Region

l North America

l Europe

l South America

l Asia Pacific

l Middle East and Africa


View full report @


Competitive Analysis

The global viral vector and plasmid DNA manufacturing market are highly competitive with several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition. Brammer Bio, Cobra Biologics, Cell and Gene Therapy Catapult, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, SIRION Biotech, Merck KGaA Inc., Thermo Fisher Scientific, and Uniqure NV are the leading market players with significant market share.

The major players enter into collaborations, acquisitions, mergers, and licensing activities to increase their market presence. For instance, in August 2019, FUJIFILM Corporation had acquired the Biogen (Denmark) Manufacturing ApS, a large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark, from Biogen. The Hillerød Manufacturing site would be the fourth biopharmaceutical manufacturing site of FUJIFILM Diosynth Biotechnologies, a Fujifilm subsidiary, and a leading Contract Development and Manufacturing Organization (CDMO) with expertise in the development and manufacture of biologics and advanced therapies.

In March 2019, Merck had entered into the non-binding Memorandum of Understanding with Chinese biotech company GenScript for a strategic alliance focusing on a plasmid and viral vector manufacturing. The manufacturing of high-quality plasmids and viral vectors would help in the commercialization of cell and gene therapy. This collaboration would help the company accelerate the industrialization and commercialization of cell and gene therapy in China. Merck would provide GenScript with comprehensive products, training, consulting services covering process design, facility concept design, and quality management system set-up from lab development to large-scale GMP manufacturing.


Trending Topic’s

Viral Inactivation Market

Viral Vector Manufacturing Market

Media Contact
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States